Novartis Ag

Other

Dana-Farber-Cancer Institute Inc.

Irm LLC

Cancer Research Campaign Technology Limited

Vernalis Limited

Carlos Garcia-Echeverria

Pascal Furet

Keiichi Masuya

Ichiro Umemura

Takanori Kanazawa

Naoko Matsuura

Osamu Ohmori

Takahiro Miyake

Eiji Kawahara

Hans-Georg Capraro

Frédéric Stauffer

Christine Fritsch

Sauveur-Michel Maira

Nathanael Schiander Gray

Paul William Manley

Donald Karanewsky

Qiong Zhang

Yongqin Wan

Qiang Ding

Ruo W Steensma

Leon Murphy

David Philip Lane

Levi A Garraway

Joseph Schoepfer

Darrin Stuart

Jiqing Jiang

Caroline Emery

Heinz-Kurt Hochkeppel

Greg Chopiuk

Paul Leslie Nicklin

Peter Finan

Patrick Chène

Angelika Böttger

Steven Michael Picksley

Michael Rugaard Jensen

Saskia Maria Brachmann

Susan Wee

Tobi Nagel

Volker Böttger

Michael Jensen

Frederic Stauffer

Cornelia Quadt

The invention relates to the use of compounds of formula (I) in the treatment of mammalian target of rapamycin (mTOR) kinase dependent diseases, methods of use of said compounds in the treatment of said diseases in a warm-blooded animal, especially a human, pharmaceutical preparations comprising said compounds for the treatment of said diseases and said compounds for use in the treatment of said diseases.

Imidazoquinolines as dual lipid kinase and mTOR inhibitors

The invention relates to a pharmaceutical combination which comprises (a) a phosphoinositide 3-kinase inhibitor compound and (b) a compound which modulates the Ras/Raf/Mek pathway for the treatment of a proliferative disease, especially a solid tumor disease; a pharmaceutical composition comprising such a combination; the use of such a combination for the preparation of a medicament for the treatment of a proliferative disease; a commercial package or product comprising such a combination as a combined preparation for simultaneous, separate or sequential use; and to a method of treatment of a warm-blooded animal, especially a human.

Combination of (a) a phosphoinositide 3-kinase inhibitor and (b) a modulator of RAS/RAF/MEK pathway

The present invention relates to methods, compositions and kits concerning resistance to treatment with an anti-cancer agent, specifically an inhibitor of MEK. In particular embodiments, the invention concerns mutations in a MEK sequence that confer resistance to a MEK inhibitor. Identification of such mutations in a MEK sequence allows the identification and design of second-generation MEK inhibitors. Methods and kits for detecting the presence of a mutant MEK sequence in a sample are also provided.

MEK mutations conferring resistance to MEK inhibitors

The invention relates to methods of treatment of a proliferative disease which responds to inhibition of PI3-Kinase-related protein kinases, particularly the PI3-kinase, by administration of a novel organic compound of formula (I) to a human or animal requiring such treatment; and methods of treatment of inflammatory or obstructive airway disease, such as asthma, disorders commonly occurring in connection with transplantation, or a proliferative disease, such as a tumor disease, by administration of such compound.

1,3-dihydro-imidazo[4,5-c]quinolin-2-ones as lipid kinase inhibitors

Novel pyrimidine derivatives of formula I to processes for their production, their use as pharmaceuticals and to pharmaceutical compositions comprising them.

Pyrimidine derivatives

The invention relates to the use of imidazoquinolines and salts thereof in the treatment of protein kinase dependent diseases and for the manufacture of pharmaceutical preparations for the treatment of said diseases, imidazoquinolines for use in the treatment of protein kinase dependent diseases, a method of treatment against said diseases, comprising administering the imidazoloquinolines to a warm-blooded animal, especially a human, pharmaceutical preparations comprising an imidazoquinoline, especially for the treatment of a protein kinase dependent disease, novel imidazoquinolines, and a process for the preparation of the novel imidazoquinolines.

1H-imidazo[4,5-c]quinoline derivatives in the treatment of protein kinase dependent diseases

The invention relates to novel organic compounds of formula (I) processes for the preparation thereof, the application thereof in a process for the treatment of the human or animal body, the use thereof&#x2014;alone or in combination with one or more other pharmaceutically active compounds&#x2014;for the treatment of an inflammatory or obstructive airway disease, such as asthma, disorders commonly occurring in connection with transplantation, or a proliferative disease, such as a tumor disease.

1,3-dihydro-imidazo[4,5-C]quinolin-2-ones as lipid kinase inhibitors

Novel pyrimidine derivatives of formula I to process for their production, their use as pharmaceuticals and to pharmaceutical compositions comprising them.

2,4-di (phenylamino) pyrimidines useful in the treatment of neoplastic diseases, inflammatory and immune system disorders

2, 4-pyrimidinediamines useful in the treatment of neoplastic diseases, inflammatory and immune system disorders

1,3-dihydro-imidazo [4,5-C] quinolin-2-ones as lipid kinase inhibitors

The invention relates to new 4-amino-5-phenyl-7-cyclobutyl-pyrrolo[2,3-d]pyrimidine derivatives, processes for the preparation thereof, the application thereof in a process for the treatment of the human or animal body, the use thereof-alone or in combination with one or more other pharmaceutically active compounds-for the treatment of a disease, especially a proliferative disease, such as a tumour disease, a method for the treatment of such diseases in mammals, especially in humans, and the use of such a compound-alone or in combination with one or more other pharmaceutically active compounds-for the preparation of a pharmaceutical composition (medicament) for the treatment especially of a proliferative disease, such as a tumour.

4-Amino-5-phenyl-7-cyclobutyl-pyrrolo(2,3-d)pyrimidine derivatives

The present invention relates to compounds capable of binding to the oncogene protein MDM2, processes for the preparation of such compounds, pharmaceutical preparations comprising such compounds, and uses of said compounds, e.g. in the therapeutic (including prophylactic) treatment of an animal or especially of the human body. The present further relates to methods of and compounds for inhibiting the growth of tumor cells which comprise the wild type p53 suppressor by interfering with the interaction between human p53 and human MDM2.

Inhibitors of the interaction between P53 and MDM2

Growing community of inventors

Basel, Switzerland

Carlos Garcia-Echeverria